>>> There is no mention in any SEC filing of Baraclude’s endorsement by the group you cited: the National AIDS Treatment Advocacy Group. Nor should there be because NATAP does not have anywhere near the same standing as AASLD in the hepatitis arena. <<<
I don't know if NATAP had anything to do with it or not. That's just where I found the article. This is the PubMed citation :
...
Clin Gastroenterol Hepatol. 2006 Aug;4(8):936-62.
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.
Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL.
Division of Gastroenterology and Hepatology, Stanford University Medical Center, CA 94304, USA. ekeeffe@stanford.edu
...
It looks to me like a bunch of Stanford liver docs. Whoever is behind it , it received substantial notice and is cited often , as I said. I'm not picking sides on which guidelines rule the day , but I'd agree that AASLD ranks near the top.
>>> To reiterate, you claimed in msg #1387 that Tyzeka is deficient and dead in the water because it is not yet included in the AASLD guidelines. I’m saying that your assertion is
BS.<<<
You're having that reading comprehension problem again. The problem I saw was that Tyzeka WAS included in the current AASLD guidelines , and was specifically declared deficient.
New head-to-head data vs. Baraclude could conceivably change things in the monotherapy space , as could some newly-discovered Baraclude SAE , but I'm not counting on it.
Market Data 
Markets 
AI
